# Clinical experiences and perceptions of ketamine treatment for depression among psychiatrists in Sweden: a multiregional interview study - URL: https://alisanburak.com/en/wcp-2026-posterler/so284 - Language: en - Last updated: not specified - Page title: Clinical experiences and perceptions of ketamine treatment for depression among psychiatrists in Sweden: a multiregional interview study | WCP 2026 Summary > Swedish clinicians view ketamine as a rapid-acting option for treatment-resistant depression, but one whose effects are often temporary and which serves as a b… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/so284) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. SO284 Brief Oral Poster PresentationPsychopharmacologyQualitative study # Clinical experiences and perceptions of ketamine treatment for depression among psychiatrists in Sweden: a multiregional interview study CLINICAL EXPERIENCES AND PERCEPTIONS OF KETAMINE TREATMENT FOR DEPRESSION AMONG PSYCHIATRISTS IN SWEDEN: A MULTI-REGIONAL INTERVIEW SURVEY Presenter: Alexandra Leinonen Country: Sweden Institution: Skaraborg Hospital, Västra Götaland Region Session: 3660 - PARALLEL SHORT ORAL POSTER SESSIONS: PSYCHOPHARMACOLOGY - Part II Date: Fri, 25.09.2026 Swedish clinicians view ketamine as a rapid-acting option for treatment-resistant depression, but one whose effects are often temporary and which serves as a bridge rather than a long-term solution. The aim is to examine clinicians’ perspectives on the use of intravenous racemic ketamine in routine psychiatric care, its perceived benefits and risks, and the importance of the subjective ketamine experience. Intravenous racemic ketamine has been used off-label for treatment-resistant depression (TRD) in Sweden since 2015. The method consists of semi-structured interviews with clinicians experienced in ketamine treatment; the poster states that participants were psychiatrists and psychiatric nurses involved in ketamine treatment, representing seven clinical centers across six Swedish regions, with 2 to 9 years of experience with ketamine and several hundred patients treated collectively; interview summaries were reviewed by the participating clinicians. The predominant protocol involves intravenous administration of 0.5 mg/kg, generally 2 to 3 times a week, commonly with 4 to 8 initial sessions. Clinicians reported observing rapid symptom reduction, sometimes even after the first infusion, but noted that benefits often lasted from days to a few weeks and waned without subsequent treatment; the abstract gives estimated antidepressant response rates of approximately 20% to 50%. The most common acute adverse effects were dissociation, nausea, and anxiety, with most reactions manageable through supportive measures or by pausing the infusion. Reported clinical dilemmas include patterns of drug-seeking and escapism, early relapse following rapid improvement, passive maintenance strategies that delay other treatments, and gaps in knowledge about long-term safety and repeated infusions; there is no consensus on dissociation, with some clinicians considering it solely an adverse effect affecting tolerability, while others associated the absence of dissociation during infusion with a poorer clinical response. In conclusion, ketamine is regarded as a valuable but limited intervention, with careful patient selection, realistic expectations, structured follow-up, and integration with other treatments recommended; the poster’s take-home message is that rapid relief does not equate to lasting recovery. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2156) How to cite this study APA 7: Leinonen, A., et al. (2026, September 25). Clinical experiences and perceptions of ketamine treatment for depression among psychiatrists in sweden: a multi-regional interview survey [Poster presentation]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2156 Vancouver: Leinonen A, et al. Clinical experiences and perceptions of ketamine treatment for depression among psychiatrists in sweden: a multi-regional interview survey [poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/2156 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/so284 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim